Ascentage Pharma Group (AAPG) (AAPGV) (ASPHF), which is backed by Takeda (TAK), has priced a $126M U.S. initial public offering. Read more here.

ET Net News Agency, 24 January 2025] HANSOH PHARMA (03692) rose 3% to HK$17.8, breaking above the 50-D SMA of HK$17.727. It hits an intra-day high of HK$17.8, and an intra-day lo ...

Tata Technologies, a global product engineering and digital services company, announced the successful conclusion of the 2nd edition of the Tata Technologies InnoVent hackathon. Focused on leveraging ...

Glp-1 Analogues Market OverviewThe Glp analogues market size is expected to be worth USD 606.3 billion by 2034.The target market was valued at USD 45.3 billion in 2024.The market is projected to grow ...

Nipah virus (NiV), has shown itself to be an emerging zoonotic virus which may yet have severe human health implications. It ...

In a report released today, Cui Cui from Jefferies maintained a Buy rating on Innovent Biologics (IVBXF – Research Report), with a price target ...

ET Net News Agency, 22 January 2025] ASCENTAGE-B (06855) rose 10.1% to HK$42.6, breaking above the 100-D SMA of HK$40.948. It hits an intra-day high of HK$42.6, and an intra-day low of HK$39.5. The ...

Takeda-backed Ascentage Pharma Group (AAPG) (OTCPK:ASPHF), which is developing treatments for blood cancer, has set terms for a $170M U.S. initial public offering. In an SEC filing, Ascentage (AAPG) ...

China's National Medical Products Administration (NMPA) approved Innovent Biologics Inc.’s NDA for Dovbleron (taletrectinib), a next-generation ROS1 tyrosine kinase inhibitor (TKI), for treating ...

Four of the top 10 drugs by prescription sales in 2025 will be from the new incretin class, according to the latest analysis by Evaluate. Consensus forecasts for Ozempic, Wegovy, Mounjaro and Zepbound ...

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...

China’s National Medical Products Administration has given the green light to Innovent Biologics, Inc.’s and Jiangsu Aosaikang Pharmaceutical Co. Ltd.’s NDA for third-generation EGFR tyrosine kinase ...